Ann Lab Med.  2020 Mar;40(2):99-100. 10.3343/alm.2020.40.2.99.

From Genetic Testing to Treatment and Prevention of BRCA-Related Breast Cancer

• Ki CS

• KMID: 2460906
• DOI: http://doi.org/10.3343/alm.2020.40.2.99

Abstract

No abstract available.

MeSH Terms

Breast Neoplasms*
Breast*
Genetic Testing*

Reference

1. Jung KW, Won YJ, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2019. Cancer Res Treat. 2019; 51:431–437.

2. Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW, et al. Basic findings regarding breast cancer in Korea in 2015: data from a breast cancer registry. J Breast Cancer. 2018; 21:1–10.

3. Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015; 372:2243–2257.

4. Yoo J, Lee GD, Kim JH, Lee SN, Chae H, Han E, et al. Clinical validity of next-generation sequencing multi-gene panel testing for detecting pathogenic variants in patients with hereditary breast-ovarian cancer syndrome. Ann Lab Med. 2020; 40:148–154.

5. US Preventive Services Task Force. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019; 322:652–665.

6. Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med. 2020; 40:114–121.